SlideShare a Scribd company logo
2
Most read
3
Most read
6
Most read
ICH Q11 DEVELOPMENT AND
MANUFACTURE OF DRUG
SUBSTANCES (SUMMARY)
Dr. Dilawar Hussain
Pharm.D, MPhil Scholar
Hamdard University (Faculty of Pharmacy)
Introduction, Scope and Target
 Harmonization of scientific and technical principles relevant to the
design, development & manufacture of drug substances as part of a total
control strategy designed to ensure product quality & consistency.
 Provide guidance on the information to be provided in CTD Sections
3.2.S.2.2 – 3.2.S.2.6
 Provide further clarification on principles & concepts described in ICH
guidelines Q6,Q8, Q9 & Q10 as they pertain to the specification,
development and manufacture of drug substance.
 To establish a commercial manufacturing process capable of consistently
producing drug substance of the intended quality.
Manufacturing Process Development
General principles
 Drug substance quality link to drug product
 Process development tools
 Approaches to development
 Drug substance critical quality attributes (CQAs)
 Linking material attributes & process parameters to drug substance CQAs
 Design space
Submission of information
 Overall process development summary
 Drug substance CQAs
 Manufacturing process history
 Manufacturing developmental studies
Process Development Tools
 Quality Risk Management (as described in ICH Q9)
 Assessing quality attributes & manufacturing process parameters.
 Increasing assurance of routine achievement of acceptable results.
 Risk assessment can be carried out early in the development and shall be
repeated as knowledge & understanding increases on the process.
 Knowledge Management (as described in ICH Q10)
 Prior knowledge & development studies which include chemical, engineering
principles and applied manufacturing experience.
Approaches to Development
 Approaches of development vary from company to company & product to product.
Traditional Approach:
 Identifying potential CQAs having impact on product quality.
 Defining appropriate manufacturing process.
 Defining a control strategy to ensure process performance & quality.
Enhanced Approach:
 Prior knowledge, experimentation and risk assessment.
 Determining linkage between material attributes & process parameters to CQAs.
 Using enhanced approach in combination with Quality Risk Management to
establish appropriate control strategy.
 Traditional & Enhanced approaches are not mutually exclusive.
Drug substance Critical Quality Attributes (CQAs)
 CQA is a physical / chemical / biological / microbiological property that should be
within an acceptance criteria to ensure the desired product quality.
 CQAs are used to guide process development.
 CQAs can be modified as the knowledge & process understanding increases.
 CQAs include the properties that can affect identity, purity, biological activity and
stability.
 Impurities are important aspect of drug substance CQAs due to their potential
impact on drug product safety.
Example: Linking Material Attributes and Process
Parameters to Drug Substance CQAs - Chemical Entity
 Process design :
 Constant concentration of
intermediate F
 Constant temperature during reflux
 Hydrolysis impurity NMT 0.30%
 Possible source of water during
reflux: Water content of
intermediate E
 Based on risk assessment, parameters affecting hydrolysis :
 Time of reflux &
 Water content of intermediate E
 The reaction was expected to follow second-order kinetics according to the
equation below:
 Where F refers to the concentration of intermediate F
 Graphical presentation
for linking the
 extent of hydrolysis to
reflux time &
 water content of
intermediate E :
 Control strategy by Traditional approach :
Dry intermediate E to a maximum water content of 1.0%
Target -reflux time to 1.5 hours & maximum of 4 hours
 Control strategy by Enhanced approach :
2nd order rate equation can be integrated (Chemical Reaction Engineering,
Levenspiel 2nd Edition, 1972)
 Solving this equation for time (t) gives maximum allowable reflux time for any
combination of water
 content & target level for hydrolysis impurity (Initial concentration of
intermediate F in reflux mixture will be essentially constant
Description of manufacturing process
and process controls
 Manufacturing process should be provided as follows,
 Process flow diagram,
 Sequential procedural narrative,
 In-process controls to be indicated in the process description,
 Scaling factors, if the process is scale dependant,
 Should include design space (if any).
Selection of starting materials and
source materials
General principles
 Selection of starting materials for synthetic drug substances
 Selection of starting materials for semi-synthetic drug substances
 Selection of source materials for Biotechnological / Biological products
Submission of information
 Justification of starting materials selection for synthetic drug substances
 Justification of starting materials selection for semi-synthetic drug Substances
 Qualification of source materials for Biotechnological / Biological products
Control Strategy
 Control strategy is a planned set of controls, derived from product and
process understanding, that assures process performance & quality. It include,
Control on material attributes
Controls implicit in the design of manufacturing process
In-process controls
Controls on drug substance
Process Validation / Evaluation
 Process validation involves the collection and evaluation of data, from the
process design stage throughout production, that establish scientific evidence
that a process is capable of consistently delivering a quality drug substance.
Process should be validated (ICH Q7) before commercial distribution.
Number of batches to be considered for validation depends on
The complexity of process,
Level of process variability,
Amount of experimental data / process knowledge available on specific
process.
For non-sterile drug substances, results of process validation are not normally
included in the dossier.
SUBMISSION OF MANUFACTURING
PROCESS DEVELOPMENT & RELATED
INFORMATION IN CTD FORMAT
Quality risk management and process development in 3.2.S.2.6.
Critical Quality Attributes in 3.2.S.2.6 & 3.2.S.3.1, 3.2.S.4.1 & 3.2.S.7 (if relevant).
Design space in 3.2.S.2.2, 3.2.S.2.4, 3.2.S.2.6, 3.2.S.4.5 (wherever the relevant
justification is applicable).
Control strategy in 3.2.S.4.5 and can also be in 3.2.S.2.2, 3.2.S.2.4, 3.2.S.2.6, 3.2.S.4.1.
Life Cycle Management
Product & process knowledge should be managed from development through
the commercial life of the product up to discontinuation.
Process performance, control strategy & suitability of design spaces should be
periodically evaluated through out the life cycle and can be done as a part of
Product Quality Review (ICH Q7).
It includes process development, technology transfer, process validation and
change management activities.
Any changes within the design space (if submitted in DMF) does not require any
approval by regional regulatory authorities.
There should be a systematic managing knowledge related to both drug
substance & manufacturing process throughout the life cycle.
ICH Q11 Slide Summary

More Related Content

PPTX
PPTX
ICH Q7 Guideline
PPTX
ICH Q9 Guidelines
PPTX
ICH Q10 GUIDELINES.pptx
PPTX
ICH Q6A & ICH Q7
PPTX
Process Validation for Beginners - FDA - EMA Approach
PPTX
Process Validation of API
PPTX
21 CFR, Part 210 and 211 current.pptx
ICH Q7 Guideline
ICH Q9 Guidelines
ICH Q10 GUIDELINES.pptx
ICH Q6A & ICH Q7
Process Validation for Beginners - FDA - EMA Approach
Process Validation of API
21 CFR, Part 210 and 211 current.pptx

What's hot (20)

PPTX
Quality by Design : Critical Material attributes ,Process parameters and its ...
PPTX
ICH Q10 guideline.pptx
PPTX
PPTX
Role of quality systems and audits in pharmaceutical manufacturing environment
PPTX
USFDA guidelines on process validation a life cycle approach
PPT
Best techniques to control Genotoxities and impact of ICH M7 guideline
PPTX
Bulk active post approval changes
PPTX
ICH- Q3 Impurity
PPTX
ICH Q7 GMP for API
PPTX
Process Analytical Technology (PAT)
PPTX
paharmaceutical packaging Medical device Packaging types of medical device p...
PPT
Validation master plan
PPTX
Change control oos oot
PPTX
Stability studies of drug ICH Q1
PPTX
Regulatory requirements for api registration
PDF
Qualification of tablet compression machine
PPTX
PROCESS VALIDATION
Quality by Design : Critical Material attributes ,Process parameters and its ...
ICH Q10 guideline.pptx
Role of quality systems and audits in pharmaceutical manufacturing environment
USFDA guidelines on process validation a life cycle approach
Best techniques to control Genotoxities and impact of ICH M7 guideline
Bulk active post approval changes
ICH- Q3 Impurity
ICH Q7 GMP for API
Process Analytical Technology (PAT)
paharmaceutical packaging Medical device Packaging types of medical device p...
Validation master plan
Change control oos oot
Stability studies of drug ICH Q1
Regulatory requirements for api registration
Qualification of tablet compression machine
PROCESS VALIDATION
Ad

Similar to ICH Q11 Slide Summary (20)

PPTX
Quality by design in computer aided drug delivery system
PPTX
QUALITY BY DESIGN qbd quality by design cad cadd
PPTX
Ich Q8 Pharmaceutical Development( comparison with Q9 and Q10 )
PPTX
Quality-by-design(QbD) in pharmaceutical development
PPTX
Pharmaceutical Quality by Design (QbD)
PPTX
QBD IN PHARMACEUTICAL DEVELOPMENT
PPTX
Quality by Design, Objective & benefits of QbD, Elements of QbD, Design tools
PPTX
Quality By Design presentation qa.pptx
PPTX
QbD.pptx
PPTX
MPH14-Quality by Design Salunkhe..pptx
PDF
CCP and CQA concept .pdf
PPTX
Seminar on quality by design
PPTX
Quality by design
PDF
Petition of the Day
PPTX
Quality by design in pharmaceutical development
PPTX
Quality by design in pharmaceutical development
PDF
ocqc_presentations_2023-v10-1of1-process-validation_s508.pdf
PPTX
Webinar validation of pharmaceutical manufacturing processes
PPTX
Quality by Design and Process Analytical Technology
Quality by design in computer aided drug delivery system
QUALITY BY DESIGN qbd quality by design cad cadd
Ich Q8 Pharmaceutical Development( comparison with Q9 and Q10 )
Quality-by-design(QbD) in pharmaceutical development
Pharmaceutical Quality by Design (QbD)
QBD IN PHARMACEUTICAL DEVELOPMENT
Quality by Design, Objective & benefits of QbD, Elements of QbD, Design tools
Quality By Design presentation qa.pptx
QbD.pptx
MPH14-Quality by Design Salunkhe..pptx
CCP and CQA concept .pdf
Seminar on quality by design
Quality by design
Petition of the Day
Quality by design in pharmaceutical development
Quality by design in pharmaceutical development
ocqc_presentations_2023-v10-1of1-process-validation_s508.pdf
Webinar validation of pharmaceutical manufacturing processes
Quality by Design and Process Analytical Technology
Ad

Recently uploaded (20)

PPTX
Uterus anatomy embryology, and clinical aspects
PPTX
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
PDF
Human Health And Disease hggyutgghg .pdf
PPTX
Imaging of parasitic D. Case Discussions.pptx
PPTX
neonatal infection(7392992y282939y5.pptx
PPTX
post stroke aphasia rehabilitation physician
PDF
شيت_عطا_0000000000000000000000000000.pdf
DOCX
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
DOC
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
PPTX
ACID BASE management, base deficit correction
PPTX
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PPTX
Pathophysiology And Clinical Features Of Peripheral Nervous System .pptx
PPTX
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
PPTX
History and examination of abdomen, & pelvis .pptx
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPTX
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
Uterus anatomy embryology, and clinical aspects
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
Human Health And Disease hggyutgghg .pdf
Imaging of parasitic D. Case Discussions.pptx
neonatal infection(7392992y282939y5.pptx
post stroke aphasia rehabilitation physician
شيت_عطا_0000000000000000000000000000.pdf
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
ACID BASE management, base deficit correction
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
Medical Evidence in the Criminal Justice Delivery System in.pdf
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
Pathophysiology And Clinical Features Of Peripheral Nervous System .pptx
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
History and examination of abdomen, & pelvis .pptx
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
15.MENINGITIS AND ENCEPHALITIS-elias.pptx

ICH Q11 Slide Summary

  • 1. ICH Q11 DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (SUMMARY) Dr. Dilawar Hussain Pharm.D, MPhil Scholar Hamdard University (Faculty of Pharmacy)
  • 2. Introduction, Scope and Target  Harmonization of scientific and technical principles relevant to the design, development & manufacture of drug substances as part of a total control strategy designed to ensure product quality & consistency.  Provide guidance on the information to be provided in CTD Sections 3.2.S.2.2 – 3.2.S.2.6  Provide further clarification on principles & concepts described in ICH guidelines Q6,Q8, Q9 & Q10 as they pertain to the specification, development and manufacture of drug substance.  To establish a commercial manufacturing process capable of consistently producing drug substance of the intended quality.
  • 3. Manufacturing Process Development General principles  Drug substance quality link to drug product  Process development tools  Approaches to development  Drug substance critical quality attributes (CQAs)  Linking material attributes & process parameters to drug substance CQAs  Design space Submission of information  Overall process development summary  Drug substance CQAs  Manufacturing process history  Manufacturing developmental studies
  • 4. Process Development Tools  Quality Risk Management (as described in ICH Q9)  Assessing quality attributes & manufacturing process parameters.  Increasing assurance of routine achievement of acceptable results.  Risk assessment can be carried out early in the development and shall be repeated as knowledge & understanding increases on the process.  Knowledge Management (as described in ICH Q10)  Prior knowledge & development studies which include chemical, engineering principles and applied manufacturing experience.
  • 5. Approaches to Development  Approaches of development vary from company to company & product to product. Traditional Approach:  Identifying potential CQAs having impact on product quality.  Defining appropriate manufacturing process.  Defining a control strategy to ensure process performance & quality. Enhanced Approach:  Prior knowledge, experimentation and risk assessment.  Determining linkage between material attributes & process parameters to CQAs.  Using enhanced approach in combination with Quality Risk Management to establish appropriate control strategy.  Traditional & Enhanced approaches are not mutually exclusive.
  • 6. Drug substance Critical Quality Attributes (CQAs)  CQA is a physical / chemical / biological / microbiological property that should be within an acceptance criteria to ensure the desired product quality.  CQAs are used to guide process development.  CQAs can be modified as the knowledge & process understanding increases.  CQAs include the properties that can affect identity, purity, biological activity and stability.  Impurities are important aspect of drug substance CQAs due to their potential impact on drug product safety.
  • 7. Example: Linking Material Attributes and Process Parameters to Drug Substance CQAs - Chemical Entity  Process design :  Constant concentration of intermediate F  Constant temperature during reflux  Hydrolysis impurity NMT 0.30%  Possible source of water during reflux: Water content of intermediate E
  • 8.  Based on risk assessment, parameters affecting hydrolysis :  Time of reflux &  Water content of intermediate E  The reaction was expected to follow second-order kinetics according to the equation below:  Where F refers to the concentration of intermediate F
  • 9.  Graphical presentation for linking the  extent of hydrolysis to reflux time &  water content of intermediate E :
  • 10.  Control strategy by Traditional approach : Dry intermediate E to a maximum water content of 1.0% Target -reflux time to 1.5 hours & maximum of 4 hours  Control strategy by Enhanced approach : 2nd order rate equation can be integrated (Chemical Reaction Engineering, Levenspiel 2nd Edition, 1972)
  • 11.  Solving this equation for time (t) gives maximum allowable reflux time for any combination of water  content & target level for hydrolysis impurity (Initial concentration of intermediate F in reflux mixture will be essentially constant
  • 12. Description of manufacturing process and process controls  Manufacturing process should be provided as follows,  Process flow diagram,  Sequential procedural narrative,  In-process controls to be indicated in the process description,  Scaling factors, if the process is scale dependant,  Should include design space (if any).
  • 13. Selection of starting materials and source materials General principles  Selection of starting materials for synthetic drug substances  Selection of starting materials for semi-synthetic drug substances  Selection of source materials for Biotechnological / Biological products Submission of information  Justification of starting materials selection for synthetic drug substances  Justification of starting materials selection for semi-synthetic drug Substances  Qualification of source materials for Biotechnological / Biological products
  • 14. Control Strategy  Control strategy is a planned set of controls, derived from product and process understanding, that assures process performance & quality. It include, Control on material attributes Controls implicit in the design of manufacturing process In-process controls Controls on drug substance
  • 15. Process Validation / Evaluation  Process validation involves the collection and evaluation of data, from the process design stage throughout production, that establish scientific evidence that a process is capable of consistently delivering a quality drug substance. Process should be validated (ICH Q7) before commercial distribution. Number of batches to be considered for validation depends on The complexity of process, Level of process variability, Amount of experimental data / process knowledge available on specific process. For non-sterile drug substances, results of process validation are not normally included in the dossier.
  • 16. SUBMISSION OF MANUFACTURING PROCESS DEVELOPMENT & RELATED INFORMATION IN CTD FORMAT Quality risk management and process development in 3.2.S.2.6. Critical Quality Attributes in 3.2.S.2.6 & 3.2.S.3.1, 3.2.S.4.1 & 3.2.S.7 (if relevant). Design space in 3.2.S.2.2, 3.2.S.2.4, 3.2.S.2.6, 3.2.S.4.5 (wherever the relevant justification is applicable). Control strategy in 3.2.S.4.5 and can also be in 3.2.S.2.2, 3.2.S.2.4, 3.2.S.2.6, 3.2.S.4.1.
  • 17. Life Cycle Management Product & process knowledge should be managed from development through the commercial life of the product up to discontinuation. Process performance, control strategy & suitability of design spaces should be periodically evaluated through out the life cycle and can be done as a part of Product Quality Review (ICH Q7). It includes process development, technology transfer, process validation and change management activities. Any changes within the design space (if submitted in DMF) does not require any approval by regional regulatory authorities. There should be a systematic managing knowledge related to both drug substance & manufacturing process throughout the life cycle.